Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination therapy** of three drugs: **vasopressin**, **methylprednisolone**, and **hydrocortisone**. It has been investigated mainly as part of protocols for improving outcomes in **in-hospital cardiac arrest**, typically administered alongside standard treatments (e.g., adrenaline/epinephrine). Vasopressin is a peptide hormone with potent vasoconstrictive properties, methylprednisolone and hydrocortisone are synthetic glucocorticoid corticosteroids used for their anti-inflammatory and hemodynamic-stabilizing effects. Clinical trials have studied the bundle, often giving vasopressin and methylprednisolone during resuscitation and hydrocortisone as an infusion for post-resuscitation shock. The combined use aims to increase return of spontaneous circulation (ROSC), survival, and maintain hemodynamic stability in critically ill patients[1][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vasopressin + methylprednisolone + hydrocortisone.